Top Stories from Western Switzerland (January 2025)

From groundbreaking partnerships in biotech and cloud solutions to the recognition of its watchmaking heritage, discover Western Switzerland’s top stories from January 2025.

German IT specialist Glueckkanja establishes a presence in Bern

Glueckkanja AG, a leading provider of Microsoft-based cloud solutions, has expanded into Bern, solidifying Western Switzerland’s status as a hub for tech innovation. Facilitated by the GGBa and the Bern Economic Development Agency, Glueckkanja’s new subsidiary aims to deliver advanced cloud and cybersecurity solutions tailored to the region’s dynamic market. The company’s expansion underscores Switzerland’s appeal as a stable, innovative, and globally connected business environment.

Fribourg: The Growth Hub of Switzerland – A Video Series (Part 1/8)

The Fribourg Growth Hub video series, launched this month, features Jerry Krattiger, Managing Director of the Fribourg Development Agency, showcasing the canton’s strengths. The inaugural episode highlights Fribourg’s remarkable demographic growth and its thriving sectors like bioeconomy and Industry 4.0. This series aims to spotlight Fribourg as a dynamic center for sustainable development and economic opportunity, with future episodes set to explore its diverse industrial landscape.

Precisia Care secures CHF 1 million to optimize hospital resource management with AI

Lausanne-based Precisia Care has raised CHF 1 million to enhance its AI-driven solutions for hospital resource management. By leveraging real-time clinical data, the start-up’s technology reduces costs, anticipates resource needs, and improves patient safety. Recognized by the Future of Health Grant, Precisia Care is gaining traction across Swiss hospitals, exemplifying the potential of AI to transform healthcare operations.

Neuchâtel’s MTTA recognized as a nationally significant research infrastructure

The MTTA project, a pioneering watchmaking initiative in Neuchâtel led by Microcity, has received CHF 1.6 million in federal funding. This recognition as a nationally significant research infrastructure highlights its role in preserving Swiss watchmaking heritage while advancing innovation. Scheduled to be housed in the state-of-the-art HDV7 building by 2028, MTTA bridges traditional craftsmanship with cutting-edge technology, reinforcing Western Switzerland’s leadership in precision manufacturing.

BrainScape Medical makes strides in long-term brain monitoring

BrainScape Medical is revolutionizing neuromonitoring and neurostimulation technologies. The company’s technology, licensed from the Wyss Center, offers a minimally invasive solution for long-term brain activity monitoring and therapeutic intervention. Its first-in-human trial demonstrated the device’s safety and efficacy, recording continuous EEG signals with full head coverage. BrainScape Medical, supported by GGBa and OCEI, is headquartered at Campus Biotech in Geneva, leveraging the region’s vibrant innovation ecosystem to advance personalized neurotherapeutics.

AB2 Bio secures USD 650 million partnership for rare disease therapy

EPFL Innovation Park-based AB2 Bio has signed a major licensing agreement with Japan’s Nippon Shinyaku for Tadekinig alfa, a novel therapy targeting a rare hyperinflammatory syndrome. With up to USD 650 million in milestone payments, this partnership accelerates the treatment’s path to market, promising life-changing solutions for young patients. Recognized for its breakthrough potential, Tadekinig alfa holds U.S. and European Orphan Drug Designations, setting a benchmark in biotech innovation.